In Devices, KPCB Lands a Big One
Once viewed as heir apparent for a top job at the merged Guidant/J&J, Dana Mead unexpectedly chose another course and will join venture capital powerhouse Kleiner Perkins as a Partner on its Life Sciences team.
You may also be interested in...
Kleiner Perkins, with two new high-profile partners, Beth Seidenberg and Dana Mead, is betting on applied genomics and personalized medicine, making major investments in molecular diagnostics, stem cell therapies, and drug-device convergence.
The Italian firm's move to license Isturisa from Novartis last year is paying dividends already and Recordati has already tripled its peak sales forecast for the Cushing's therapy.